NoPrescriptionDrugstore.com Order Status FAQ Online Drugstore Affiliate Program Contact NoPrescriptionDrugstore.com No Prescription Drugs Newsletter Refer a Friend
 
Wednesday, March 26, 2008  
No Prescription - Premature Male Babies At Greater Risk Of Cardiovascular Complications
Premature Male Babies At Greater Risk Of Cardiovascular Complications
Hunter researchers have discovered that male babies born prematurely are more vulnerable to cardiovascular complications than female babies.This finding may explain why male babies born prematurely are twice as likely to die as female babies in the first 72 hours of life. It could also lead to new ways of treating premature babies throughout the world.
Source: www.medicalnewstoday.com

NEREUS Debuts To Provide Insights On The Technologies, Practices, Persons And Companies That Are Redefining The Bioprocess Industries
Nereus Consulting, LLC announced the debut of NEREUS, a monthly e-publication profiling the Technologies, Practices, Persons and Companies that are redefining the bioprocess industries of Biotechnology, Pharmaceuticals, Brewing and Biofuels. While NEREUS is provided to subscribers at no charge the specialized nature of its content is expected to limit the monthly distribution to 15,000 bioprocess professionals.
Source: www.medicalnewstoday.com

Biotech Career Fair Features Largest Employers In Life Sciences Industry
The sixth annual BIO Career Fair will feature more than 50 potential employers representing pharmaceuticals, food and agriculture, consumer products, biopreparedness, and energy, among other fields. The BIO Career Fair will take place 3 - 8 pm on Monday, June 16, 2008 at the Manchester Grand Hyatt in San Diego, Calif. in conjunction with the 2008 BIO International Convention - the global event for biotechnology.
Source: www.medicalnewstoday.com

AVI BioPharma Announces Close Of Ercole Biotech Acquisition
AVI BioPharma, Inc. (Nasdaq: AVII) announced the closing on March 20, 2008 of the previously announced merger transaction between AVI and Ercole Biotechnology Inc. Under the terms of the agreement, AVI is issuing $7.4 million in AVI common stock valued at $1.3161 per share in exchange for all outstanding shares of Ercole stock not already owned by AVI. In addition, AVI has assumed responsibility for $1.
Source: www.medicalnewstoday.com


Subscribe to Posts [Atom]

Home | Order Status | FAQ | Affiliates | Contact us | Newsletter | Refer a Friend

© 2004 Online Pharmacy. All Rights Reserved.